New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
07:58 EDTHUMHumana price target raised to $125 from $110 at Argus
Argus increased its price target on Humana as the firm expects the company's earnings to rise this year, driven by strong membership growth and low medical utilization. The firm reports that the company's membership has grown impressively in recent months, and it keeps a Buy rating on the stock.
News For HUM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
16:44 EDTHUMStocks end week lower as GDP revision closes May on down note
Subscribe for More Information
16:19 EDTHUMOn The Fly: Top stock stories for Friday
Stocks on Wall Street began the final trading day of May with slight losses. The averages began to pick up downside momentum after revised GDP numbers confirmed expectations that the economy shrank in the first quarter of the year. The Wall Street adage of “sell in May, then go away” appeared to be taking hold as the S&P broke a support level and took the other averages with it. Investors are now concerned about a June swoon, as it is historically one of the worst performing months of the year. ECONOMIC EVENTS: In the U.S., the second estimate of gross domestic product showed it shrank at a 0.7% seasonally adjusted annual rate in the first quarter. This was down from the previous estimate that output grew 0.2% from January through March, but better than the revision to a 1% decline that had been forecast by analysts. The Chicago PMI unexpectedly dropped 6.1 points to 46.2 in May, versus expectations for it to have risen to a reading of 53. The University of Michigan's consumer sentiment reading came in with a 90.7 reading for the final May print, which was up from the preliminary 88.6 reading for the month but down from April's 95.9 figure. COMPANY NEWS: Shares of Humana (HUM) jumped $36.24, or 20.31%, to $214.65 after The Wall Street Journal said the company has hired Goldman Sachs (GS) to help it explore a potential sale after receiving indications of takeover interest. Some of the Journal's sources reportedly said Aetna (AET) and Cigna (CI) are among possible bidders for Humana. Bloomberg then said Humana's sale exploration came after Cigna made a takeover approach. Leerink analyst Ana Gupte wrote in a note to investors on May 12 that consolidation in the industry remains likely, adding that a deal between Aetna and either Cigna or Humana were both "meaningfully accretive" and "imminent" possibilities. MAJOR MOVERS: Among the notable gainers was Heron Therapeutics (HRTX), which gained $7.41, or 60%, to $19.76 after the company reported positive top-line data from a Phase 3 marketing study looking at Sustol as part of a 3-drug regimen for the prevention of delayed-onset chemotherapy-induced nausea and vomiting following administration of highly emetogenic chemotherapy agents. Also higher was Altera (ALTR), which advanced $1.88, or 4%, to $48.85 after reports from The New York Post and Financial Times claimed the company is near a deal to be acquired by chipmaking giant Intel (INTC) for up to $54 per share. Reuters, meanwhile, revised its prior report to indicate the potential price of the deal could be close to $16B. Among the noteworthy losers was Abercrombie & Fitch (ANF), which fell $1.63, or 7.38%, to $20.47 after Janney Capital downgraded the stock to Sell from Hold and warned the company's comparative sales may continue to drop year-over-year as it changes nearly every aspect of its business. Also lower were shares of Bristol-Myers Squibb (BMY), which dropped $4.55, or 6.58%, to $64.60 after the company reported data from a Phase III study evaluating Opdivo in previously-treated patients with advanced, non-squamous non-small cell lung cancer. Biotech analyst Mark Schoenebaum reportedly said Bristol-Myers' data from its Checkmate 057 study opens the door for lung cancer competition from Merck (MRK) and Roche (RHHBY), according to TheStreet's Adam Feuerstein. INDEXES: The Dow dropped 115.44, or 0.64%, to 18,010.68, the Nasdaq lost 27.95, or 0.55%, to 5,070.03, and the S&P 500 fell 13.40, or 0.63%, to 0.63.
15:30 EDTHUMExpress Scripts options active after report of possible Humana sale
Express Scripts (ESRX) June 90 weekly and July weekly 83 puts are active on 14K puts (6K calls) after a report of possible Humana (HUM) sale. June and July put option implied volatility is at 23; compared to its 52-week range of 14 to 32. Active put volume suggests traders taking positions for downside price movement.
15:15 EDTHUMAetna options active following report Humana considering possible sale
Subscribe for More Information
15:11 EDTHUMAmerisourceBergen reverses after report of potential Humana sale
Subscribe for More Information
15:00 EDTHUMExpress Scripts falling, Anthem rising after report of possible Humana sale
Subscribe for More Information
14:38 EDTHUMCigna options active following report Humana considering possible sale
Subscribe for More Information
14:11 EDTHUMHumana options after report of considering possible sale
Humana June 205, July 210 calls and June 160 and 167.5 puts are active on total call volume of 10K contracts (32K puts) on considering sale after receiving takeover interest, WSJ reports. June call option implied volatility is at 42, July is at 38; compared to its 52-week range of 18 to 34. Active option volume suggests traders taking positions for large price movement.
13:58 EDTHUMHumana sale exploration comes after Cigna takeover approach, Bloomberg says
Subscribe for More Information
13:50 EDTHUMHumana surges after report says sale being explored
Shares of health insurer Humana (HUM) are surging in afternoon trading after a report claimed the company is exploring a potential sale after receiving indications of takeover interest. WHAT'S NEW: The Wall Street Journal, citing sources, reported that Humana has hired Goldman Sachs (GS) to help it explore a potential sale after receiving indications of interest. Some of the Journal's sources reportedly said Aetna (AET) and Cigna (CI) are among possible bidders. WHAT'S NOTABLE: After meeting with Aetna's (AET) management, Leerink analyst Ana Gupte wrote in a note to investors on May 12 that consolidation in the industry remains likely, adding that a deal between Aetna and either Cigna or Humana were both "meaningfully accretive" and "imminent" possibilities. The next day, Sterne Agee analyst Brian Wright said Humana was unlikely to be acquired with its stock where it has recently been trading. Wright, who added that speculation about a takeover is "wishful thinking," downgraded Humana shares to Underperform, the firm's sell equivalent rating, and cut his price target on the stock to $150 from $165. OTHERS TO WATCH: Other publicly traded companies in the space include Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG). PRICE ACTION: In afternoon trading, Humana jumped 17.33% to $209.33, Aetna rose 2.1% to $118.84 and Cigna gained 4.45% to $141.91.
13:18 EDTHUMHumana resumes, up 15% to $205 after report of considering possible sale
Subscribe for More Information
13:17 EDTHUMHumana considering sale after receiving takeover interest, WSJ reports
Humana (HUM) is working with advisers at Goldman Sachs (GS) to consider a potential sale after receiving indications of takeover interest, reported The Wall Street Journal, citing people familiar with the matter. Some of the people said Aetna (AET) and Cigna (CI) are among possible bidders for Humana, the report added. In afternoon trading, Humana jumped 5% before being halted for volatility, while Aetna rose nearly 1% and Cigna gained about 2%. Reference Link
13:12 EDTHUMHumana working with Goldman on potential sale after takeover interest, DJ says
Subscribe for More Information
13:11 EDTHUMHumana halted after jumping 5% after Dow Jones says takeover interest received
Subscribe for More Information
May 19, 2015
12:04 EDTHUMAnthem CFO says 'good time' for 'meaningful' acquisition, Reuters reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use